Filtered By:
Condition: ALS

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 644 results found since Jan 2013.

Effects of vitamin E on neurodegenerative diseases: an update
Acta Neurobiol Exp (Wars). 2021;81(1):21-33. doi: 10.21307/ane-2021-003.ABSTRACTVitamin E deficiency is associated with many neurological problems. Although the mechanisms of vitamin E action in neurodegenerative diseases are not clear, there are many possible mechanisms. Examples of such mechanisms are the protective effects of vitamin E against oxidative stress damage and its suppressive role in the expression of many genes involved in the development of neurodegeneration. Many studies have evaluated the relationship between vitamin E intake or vitamin E levels in body fluids and neurodegenerative diseases. Some studies ...
Source: Acta Neurobiologiae Experimentalis - May 5, 2021 Category: Neurology Authors: Mehmet Arif Icer Neslihan Arslan Makbule Gezmen-Karadag Source Type: research

Paraoxonase 1 in neurological disorders.
Abstract Paroxonase 1 displays multiple physiological activities that position it as a putative player in the pathogenesis of neurological disorders. Here we reviewed the literature focusing on the role of paraoxonase 1 (PON1) as a factor in the risk of stroke and the major neurodegenerative diseases. PON1 activity is reduced in stroke patients, which significantly correlates inversely with carotid and cerebral atherosclerosis. The presence of the R allele of the Q192R PON1 polymorphism seems to potentiate this risk for stroke. PON1 exerts peroxidase activities that may be important in neurodegenerative disorders ...
Source: Redox Report : communications in free radical research - November 12, 2013 Category: Biochemistry Authors: Menini T, Gugliucci A Tags: Redox Rep Source Type: research

Use of Veterans Specific Activity Questionnaire VSAQ to Estimate Exercise Tolerance in Ambulatory Amyotrophic Lateral Sclerosis (ambALS) Patients (P2.071)
CONCLUSIONS:VSAQ is a practical tool to estimate exercise capacity of ambALS and may be used for safe exercise prescription.Disclosure: Dr. Sanjak has nothing to disclose. Dr. Headen has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Langford has nothing to disclose. Dr. Bravver has received research support from Biogen Idec, Avanier, Cytokinetics Pharmaceuticals, Neuraltus Pharmaceuticals, GlaxoSmithKline Inc., the National Institute of Neurological Disorders and Stroke, and the Clinical Research Consortium. Dr. Bockenek has nothing to disclose. Dr. Desai has received pe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Headen, J., Barrett, K., Holsten, S., Langford, V., Bravver, E., Bockenek, W., Desai, U., Story, J. S., Lindblom, S. C., Paccico, T., Brooks, B. Tags: ALS: Genetics and Outcomes Source Type: research

Walking Capacity WalkCap Measured by Six-Minute Walk (6MW) Does Not Demonstrate Fatigue in Patients with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS),and Parkinson Disease (PD) (P3.071)
CONCLUSIONS:WalkCap of ambulatory ALS, MS, and PD during 6MW is not affected by motor fatigue. WalkCap was higher in ambulatory patients with stronger grip, faster in TUG and 25FW. WalkCap measured by 6MW can be used as a simple outcome measure to evaluate lower extremity impairments in various neurological diseases. Discordance between WalkCap and the UPDRS-motor scale in mildly affected PD patients indicates that 6MW may provide additional information regarding these patients in clinical practice and clinical research trials.Study Supported by:Carolinas ALS Research Fund, Pinstripes Fund, Carolinas Healthcare Foundation,...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Morgan, L., Simpson, A., Holsten, S., Hirsch, M., Englert, D., Iyer, S., Conway, J., Kaufman, M., Bravver, E., Desai, U., Russo, P., Brooks, B. Tags: Movement Disorders: Assessing Parkinson ' s Disease Source Type: research

Serum Creatinine, a Biomarker for Muscle Mass in Amyotrophic Lateral Sclerosis (ALS), Predicts Loss of Ambulation Measured by ALS Functional Rating Scale-Revised Walking Item Score (ALSFRS-Rw) (P4.085)
CONCLUSIONS:Decrease in serum creatinine significantly predicted change in ambulation measured by ALSFRS-Rw longitudinally.Further analysis is required to determine whether leg function alone and leg muscle mass are the major determinants of serum creatinine in ALS patients over the course of the disease.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Dis...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Brooks, B., Fischer, M., Sanjak, M., Holsten, S., Kandinov, B., Bockenek, W., Bravver, E., Desai, U., Story, J. S., Pacicco, T., Lindblom, S., Langford, V., Wright, K., Ward, A., Lucas, N., Smith, N., Nichols, M., Lary, C., Nemeth, J., Russo, P. Tags: ALS: Trials and Biomarkers Source Type: research

Peculiarities of Neurological Disorders and Study Designs.
The objectives of treatments of neurodegenerative disorders include primary prevention, slowing or arrest of disease progression, and control of symptoms. Stroke is an acute clinical condition causing frequent disability and death, with only one approved treatment. There are many challenges to acute stroke clinical trials; among them, the very short therapeutic window and the issue of stroke heterogeneity. In this chapter, only the core elements of the study designs are outlined. KEY MESSAGES: The design of an RCT must be adapted to the basic characteristics of each clinical condition. PMID: 27463686 [PubMed - in process]
Source: Frontiers of Neurology and Neuroscience - July 29, 2016 Category: Neuroscience Tags: Front Neurol Neurosci Source Type: research

3K3A –activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice
Nature Medicine 22, 1050 (2016). doi:10.1038/nm.4154 Authors: Yaoming Wang, Zhen Zhao, Sanket V Rege, Min Wang, Gabriel Si, Yi Zhou, Su Wang, John H Griffin, Steven A Goldman & Berislav V Zlokovic Activated protein C (APC) is a blood protease with anticoagulant activity and cell-signaling activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1) and F2RL1 (also known as PAR3) via noncanonical cleavage. Recombinant variants of APC, such as the 3K3A-APC (Lys191–193Ala) mutant in which three Lys residues (KKK191–193) were replaced with alanine, and/or its other mutan...
Source: Nature Medicine - August 21, 2016 Category: Journals (General) Authors: Yaoming Wang Zhen Zhao Sanket V Rege Min Wang Gabriel Si Yi Zhou Su Wang John H Griffin Steven A Goldman Berislav V Zlokovic Tags: Letter Source Type: research